The significant increase in sales results from the sustainable growth in demand for radioisotopes for pharmaceutical and industrial applications. This is offset by a lower gross margin due to a weaker product mix in the Isotope Products segment. The main drivers of the decline in earnings compared to the previous year are however losses in the context of valuations of balance sheet items in foreign currencies and inflation adjustments in the hyperinflationary country of Argentina, which were not included in the first quarter of the previous year, totaling around EUR 1.5 million.

Sales in the Medical segment amounted to EUR 24.1 million in the first three months of the year, around EUR 4 million or 20% above the level of the previous year. The main growth driver continues to be the pharmaceutical radioisotope business, and sales of laboratory equipment also increased again. There were slight declines in the Radiation Therapy segment, due to the sale of Wolf-Medizintechnik GmbH and the HDR business.

The Isotope Products segment generated sales of EUR 33.8 million, a rise of EUR 4 million or around 13% compared to the first three months of 2022. Almost all main product groups contributed to this good performance. In contrast, high-margin sales of radiation sources for use in the energy sector recorded a significantly weaker first quarter than in the previous year.

The forecast for fiscal year 2023 published on March 30, 2023 remains unchanged. The Executive Board continues to expect sales of just under EUR 230 million and net income of around EUR 25 million.

The complete quarterly report can be viewed here:
https://www.ezag.com/fileadmin/user_upload/ezag/investors-financial-reports/englisch/euz123e.pdf